Abstract:Objective To identify whether regulation of Cathepsin G (CatG) expression can influence CD4+T lymphocytes(T cells)activation in non-obese diabetic(NOD)mice,and to demonstrate the role of CatG inhibition in prevention and treatment for type 1 diabetes mellitus(T1DM).Methods A total of 36 female NOD mice (6 weeks old) were randomly divided into 3 groups according to the duration and blood glucose: normal control group, pre-diabetes (pre-DM) group, and diabetes (DM) group. CatG gene expression and CD4+T cells activation were examined in these three groups of NOD mice(12 mice in each group). After modelling, CatG small interfering RNA (siRNA) was administrated to treat the other pre-diabetic NOD mice,and CatG inhibitor was administrated to treat diabetic NOD mice(12 mice in each intervention group).Also control groups(12 mice in each group)were respectively set.After 8 weeks,all the mice were executed and histological analysis were performed.The effect of CatG inhibitor was investigated in NOD mice on CD4+ T cells activation, islet β cell function, and islet inflammation. Furthermore, NOD mice were injected with CatG siRNA in early stage to observe the effect of CatG knockdown on CD4+T cells activation status and on diabetes progression. The data of three groups were analyzed with single factor analysis of variance, and the data of two groups were compared with independent samples t test. Results (1)The gene level of CatG of the 3 groups was 0.42±0.21,0.60±0.33,0.94±0.45,respectively(F=12.89,P<0.05).The gene level of CatG in pre-DM group and DM group was significantly higher than that in normal control group. Meanwhile, compared with normal control group, the CD4+ T cells in spleen and peripheral blood were gradually activated in pre-DM group and DM group,resulting in more T helper(Th)1 cells and fewer Th2 and regulatory T(Treg) cells (F=11.85-21.36, all P<0.01). (2) After administration with CatG inhibitor,the level of blood glucose was decreased(t=11.26-12.45,all P<0.01)and insulin was increased(t=11.89-13.78, all P<0.01);Meanwhile, the activation of CD4+ T cells was decreased, and the difference was statistically significant (all P<0.05). (3) Compared with the control group, after early application of CatG siRNA, the percentage of Th1 cells was decreased [peripheral blood:(5.1 ± 1.4)% vs (2.4 ± 0.3)%, spleen:(10.6 ± 2.0)% vs(6.3 ± 1.5)%, t=20.78, 27.96, all P<0.05]. The percentage of Th2 and Treg cells was increased (t=20.59-30.25, all P<0.05). Meanwhile, the mice could maintain in normal glucose status or pre-DM status,and the insulin level could be enhanced significantly in CatG siRNA group(t=31.69-33.98, all P<0.01).Conclusion CatG is the major effector protease in CD4+T cells activation in the pathogenesis of T1DM.Targeted inhibition of CatG may delay or block T1DM progression through alleviating CD4+T cells activation.

GAD-IgG-inducing CD4+Foxp3+Treg Cells Suppressing Diabetes Are Involved in the Increasing Ratio of CD80+:CD86+ Cells in NOD Mice

CD8+ Regulatory T Cells Are Responsible for GAD‐IgG Gene‐transferred Tolerance Induction in NOD Mice

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

Diabetes is Not Prevented by Foxp3-Transduced Cd4(+)T Cells under the Il-12r Beta 2 Promoter Control

Diabetes is Not Prevented by Foxp3-transduced CD4+T Cells under the IL-12Rβ2 Promoter Control

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Interleukin‐17‐producing Γδ+ T Cells Protect NOD Mice from Type 1 Diabetes Through a Mechanism Involving Transforming Growth Factor‐β

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4(+)CD25(+) Regulatory T Cells.

Vaccination with A Co-Expression Dna Plasmid Containing Gad65 Fragment Gene and Il-10 Gene Induces Regulatory Cd4(+) T Cells That Prevent Experimental Autoimmune Diabetes

Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice Treated with Alpha-Galactosylceramide.

Converting Antigen-Specific Diabetogenic CD4 and CD8 T Cells to TGF-beta Producing Non-Pathogenic Regulatory Cells Following FoxP3 Transduction.

The Role of STAT3 in Antigen-Igg Inducing Regulatory CD4+Foxp3+T Cells

Resistance of Diabetes in Aged NOD Mice is Mediated by CD4+CD25+Foxp3+ Regulatory T Cells (P4144)

Active Tolerance Induction and Prevention of Autoimmune Diabetes by Immunogene Therapy Using Recombinant Adenoassociated Virus Expressing Glutamic Acid Decarboxylase 65 Peptide Gad(500-585)

Role of Cathepsin G in the Activation of CD4+T Lymphocytes in Mice with Type 1 Diabetes

Mechanisms underlying B-cell tolerance induction by antigen-immunoglobulin G gene transfer

Tolerogenic Vaccination Reduced Effector Memory Cd4 T Cells and Induced Effector Memory Treg Cells for Type I Diabetes Treatment

Endogenous immune response to glutamic acid decarboxylase (GAD67) in NOD mice is modulated by adjuvant immunotherapy

Transient B-cell depletion and regulatory T-cells mediation in combination with adenovirus mediated IGF-1 prevents and reverses autoimmune diabetes in NOD mice

Downregulation of Cathepsin G Reduces the Activation of CD4+T Cells in Murine Autoimmune Diabetes